Illumina, Inc. $ILMN Shares Acquired by AQR Capital Management LLC

AQR Capital Management LLC increased its stake in shares of Illumina, Inc. (NASDAQ:ILMN) by 55.3% during the second quarter, Holdings Channel.com reports. The institutional investor owned 3,295,880 shares of the life sciences company’s stock after buying an additional 1,174,295 shares during the quarter. AQR Capital Management LLC’s holdings in Illumina were worth $313,290,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Envestnet Portfolio Solutions Inc. boosted its position in Illumina by 0.8% in the second quarter. Envestnet Portfolio Solutions Inc. now owns 12,074 shares of the life sciences company’s stock valued at $1,152,000 after buying an additional 99 shares during the last quarter. Parkside Financial Bank & Trust boosted its position in Illumina by 65.7% in the 2nd quarter. Parkside Financial Bank & Trust now owns 290 shares of the life sciences company’s stock worth $28,000 after purchasing an additional 115 shares in the last quarter. Arkadios Wealth Advisors grew its stake in shares of Illumina by 1.7% during the 2nd quarter. Arkadios Wealth Advisors now owns 9,130 shares of the life sciences company’s stock worth $871,000 after purchasing an additional 157 shares during the period. Tokio Marine Asset Management Co. Ltd. raised its position in shares of Illumina by 3.0% in the first quarter. Tokio Marine Asset Management Co. Ltd. now owns 5,604 shares of the life sciences company’s stock worth $445,000 after acquiring an additional 164 shares during the period. Finally, IMA Advisory Services Inc. grew its holdings in Illumina by 6.2% in the second quarter. IMA Advisory Services Inc. now owns 2,853 shares of the life sciences company’s stock valued at $272,000 after purchasing an additional 167 shares during the period. Hedge funds and other institutional investors own 89.42% of the company’s stock.

Insiders Place Their Bets

In other news, Director Scott Gottlieb bought 500 shares of Illumina stock in a transaction that occurred on Monday, November 3rd. The shares were purchased at an average price of $122.13 per share, with a total value of $61,065.00. Following the completion of the acquisition, the director directly owned 12,523 shares in the company, valued at $1,529,433.99. The trade was a 4.16% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. 2.60% of the stock is currently owned by company insiders.

Illumina Price Performance

ILMN stock opened at $134.87 on Friday. The company has a current ratio of 1.43, a quick ratio of 1.12 and a debt-to-equity ratio of 0.42. The company has a market capitalization of $20.61 billion, a PE ratio of 30.24, a P/E/G ratio of 2.44 and a beta of 1.44. The business’s fifty day moving average price is $114.71 and its 200 day moving average price is $102.61. Illumina, Inc. has a 12-month low of $68.70 and a 12-month high of $153.06.

Illumina (NASDAQ:ILMN) last released its earnings results on Thursday, October 30th. The life sciences company reported $1.34 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.16 by $0.18. The company had revenue of $1.08 billion for the quarter, compared to analyst estimates of $1.07 billion. Illumina had a net margin of 16.40% and a return on equity of 29.21%. The firm’s quarterly revenue was up .4% on a year-over-year basis. During the same period in the prior year, the business earned $1.14 EPS. Illumina has set its FY 2025 guidance at 4.650-4.750 EPS. On average, sell-side analysts anticipate that Illumina, Inc. will post 4.51 EPS for the current year.

Analysts Set New Price Targets

A number of brokerages have recently issued reports on ILMN. UBS Group increased their target price on Illumina from $110.00 to $120.00 and gave the company a “neutral” rating in a research report on Friday, October 31st. Cowen reiterated a “hold” rating on shares of Illumina in a research note on Friday, October 31st. JPMorgan Chase & Co. raised their target price on Illumina from $100.00 to $105.00 and gave the company a “neutral” rating in a research report on Friday, October 31st. Barclays boosted their price target on Illumina from $95.00 to $100.00 and gave the stock an “underweight” rating in a research report on Friday, October 31st. Finally, Evercore ISI boosted their price target on shares of Illumina from $132.00 to $142.00 and gave the stock an “outperform” rating in a research report on Friday, October 31st. One research analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, thirteen have given a Hold rating and two have assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold” and an average target price of $115.00.

Illumina Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.